Biogen Shares Surge 40% on Positive lecanemab Data
<p><a href='https://financialmodelingprep.com/financial-summary/BIIB'>Biogen Inc. (NASDAQ:BIIB)</a> shares closed nearly 40% higher on Wednesday following the positive outcome of ph.III study of lecanemab in Alzheimer's disease, with highly statistically significant results across the board.</p>
<p>Analysts at RBC Capital believe this should support a high likelihood of full approval, CMS reimbursement, and $8 billion in out-year WW end-user sales, and should transform the company into an earnings growth story again starting in 2024. </p>
<p>The analysts expect significant stock upside, raising their price target to $321 from $251, while reiterating their outperform rating.</p>

NASDAQ:BIIB